Eline Dejonckheere

1.5k total citations · 1 hit paper
11 papers, 1.2k citations indexed

About

Eline Dejonckheere is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Eline Dejonckheere has authored 11 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in Eline Dejonckheere's work include Protease and Inhibitor Mechanisms (4 papers), Peptidase Inhibition and Analysis (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Eline Dejonckheere is often cited by papers focused on Protease and Inhibitor Mechanisms (4 papers), Peptidase Inhibition and Analysis (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Eline Dejonckheere collaborates with scholars based in Belgium, Germany and United States. Eline Dejonckheere's co-authors include Claude Libert, Lien Dejager, Iris Pinheiro, Roosmarijn E. Vandenbroucke, Filip Van Hauwermeiren, Elien Van Wonterghem, Riet De Rycke, Carlos López-Otı́n, Georges Leclercq and Kris Gevaert and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Neuroscience and European Respiratory Journal.

In The Last Decade

Eline Dejonckheere

11 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?

2011 564 citations Lien Dejager, Iris Pinheiro et al. Trends in Microbiology profile →

Peers

Countries citing papers authored by Eline Dejonckheere

Since Specialization

Citations

This map shows the geographic impact of Eline Dejonckheere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eline Dejonckheere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eline Dejonckheere more than expected).

Fields of papers citing papers by Eline Dejonckheere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eline Dejonckheere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eline Dejonckheere. The network helps show where Eline Dejonckheere may publish in the future.

Co-authorship network of co-authors of Eline Dejonckheere

This figure shows the co-authorship network connecting the top 25 collaborators of Eline Dejonckheere. A scholar is included among the top collaborators of Eline Dejonckheere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eline Dejonckheere. Eline Dejonckheere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors 2025 ·Molecular Cancer Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Diane Van Hoorick, Joseph D. Batchelor, E. Svidritskiy, Yu Qiu, Eline Dejonckheere, (unknown), Lily Pao, Marie-Ange Buyse	1
2	Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile 2024 ·Blood Advances ·Zhihong Zeng, (unknown), (unknown), (unknown), S. Guérif, Veronique De Brabandere, Céline Amara, Eline Dejonckheere, Angéla Virone-Oddos, Marielle Chiron, Marina Konopleva, Mélissa Dullaers	17
3	Pharmacokinetic and pharmacodynamic modelling of the novel anti-ADAMTS-5 nanobody M6495 using the neo-epitope ARGS as a biomarker 2018 ·Osteoarthritis and Cartilage ·Joao N.S. Pereira, (unknown), Benedikte Serruys, Eline Dejonckheere, Anne‐Christine Bay‐Jensen, Anne Sofie Siebuhr, Samer El Bawab, C. Ladel, S. Lindemann	6
4	Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8 2016 ·Molecular Therapy ·Delphine Demeestere, Eline Dejonckheere, Sophie Steeland, Paco Hulpiau, Jurgen Haustraete, Nick Devoogdt, Rielana Wichert, Christoph Becker‐Pauly, Elien Van Wonterghem, Sylviane Dewaele, Griet Van Imschoot, Jeroen Aerts, Lut Arckens, Yvan Saeys, Claude Libert, Roosmarijn E. Vandenbroucke	19
5	Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF 2013 ·EMBO Molecular Medicine ·Roosmarijn E. Vandenbroucke, Eline Dejonckheere, Filip Van Hauwermeiren, Sofie Lodens, Riet De Rycke, Elien Van Wonterghem, An Staes, Kris Gevaert, Carlos López-Otı́n, Claude Libert	115
6	Matrix Metalloprotease 8-Dependent Extracellular Matrix Cleavage at the Blood-CSF Barrier Contributes to Lethality during Systemic Inflammatory Diseases 2012 ·Journal of Neuroscience ·Roosmarijn E. Vandenbroucke, Eline Dejonckheere, Philippe Van Lint, Delphine Demeestere, Elien Van Wonterghem, (unknown), Leen Puimège, Filip Van Hauwermeiren, Riet De Rycke, Conor Mc Guire, Cristina Campestre, Carlos López-Otı́n, Patrick Matthys, Georges Leclercq, Claude Libert	95
7	Matrix metalloproteinases as drug targets in ischemia/reperfusion injury 2011 ·Drug Discovery Today ·Eline Dejonckheere, Roosmarijn E. Vandenbroucke, Claude Libert	101
8	Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression 2011 ·Cytokine & Growth Factor Reviews ·Eline Dejonckheere, Roosmarijn E. Vandenbroucke, Claude Libert	81
9	A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? 2011 ·European Respiratory Journal ·Roosmarijn E. Vandenbroucke, Eline Dejonckheere, Claude Libert	94
10	Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? breakdown → 2011 ·Trends in Microbiology ·Lien Dejager, Iris Pinheiro, Eline Dejonckheere, Claude Libert	564
11	Type I interferon drives tumor necrosis factor–induced lethal shock 2009 ·The Journal of Experimental Medicine ·(unknown), Filip Van Hauwermeiren, Lien Dejager, Eline Dejonckheere, Stefan Lienenklaus, Siegfried Weiß, Georges Leclercq, Claude Libert	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact